AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics

AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
10.14BUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US03770N1019
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
13.21
Dividend Share
-
Dividend Yield
-
Earnings Share
-4.32
Wall Street Target Price
130.53
EPS Estimate Current Year
-4.41
EPS Estimate Next Year
-5.19
EPS Estimate Current Quarter
-1.1313
EPS Estimate Next Quarter
-1.1839
Most Recent Quarter
-
Revenue TTM
0
Gross Profit TTM
0
EBITDA
-303,652,000
Profit Margin
0.00%
Return On Assets TTM
-19.00%
Return On Equity TTM
-28.47%
Revenue Per Share TTM
0
Qtly Revenue Growth YOY
0.00%
Diluted Eps TTM
-4.32
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0
Price Book MRQ
8.1204
Enterprise Value Revenue
0
Enterprise Value EBITDA
0
523.91
5.61%359.00
3.08%808.05
3.02%93.67
2.24%57.97
2.11%206.97
0.89%23.72
0.85%129.82
0.50%866.11
0.12%266.09
-1.21%